AZM198
AZM198 is a selective, orally active, and irreversible MPO inhibitor with an IC50 of 15.0 nM. AZM198 has an IC50 of 19 μM for CYP3A4. AZM198 has favorable lipophilicity, membrane permeability, metabolic stability, safety, and pharmacokinetic properties. AZM198 exhibits activity in improving vascular function, atherosclerotic plaques, pulmonary hypertension, kidney disease, visceral inflammatory fat deposition, ectopic fat deposition, and hepatic fibrosis[1].
Product Specifications
CAS Number
1933460-23-1
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Cytochrome P450; Glutathione Peroxidase
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Field of Research
Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease
Smiles
O=C1NC(N(CC2=CC=C(C=C2CN)Cl)C3=C1NC=C3)=S
Molecular Formula
C14H13ClN4OS
Molecular Weight
320.80
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CYP3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
